Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L606 Single Ascending Dose in Healthy Subjects
NCT04041648Phase 1Completed
- Sponsor
- Pharmosa Biopharm Inc.
- Start
- Nov 2018
- Primary completion
- Sep 2019
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing L606 with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Nov 2018; status: completed.
02
Drugs
L606
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04041648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04041648.